# GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

> **NCT04083599** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 350 (actual)

## Conditions studied

- Malignant Solid Tumor
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Melanoma
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **BIOLOGICAL:** GEN1042
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** 5-FU
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04083599
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-17
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-11
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083599, "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04083599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*